1-20 of 30
Alexander Drilon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT228: Concordance between tissue and circulating tumor DNA (ctDNA) testing for neurotrophic tyrosine receptor kinase (NTRK) gene fusions in larotrectinib (laro) clinical trials

Erin R. Rudzinski, Marc Ladanyi, Lauren L. Ritterhouse, Felix Sahm, Ricarda Norenberg, Hong Zheng, Chi Chen, Vadim Bernard-Gauthier, Nicoletta Brega, Cornelis M. van Tilburg, Jessica J. Lin, Marcia S. Brose, Ulrik N. Lassen, Ray McDermott, Theodore W. Laetsch, David S. Hong, Alexander Drilon, Sinchita Roy-Chowdhuri
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT228.
https://doi.org/10.1158/1538-7445.AM2023-CT228
Published: 14 April 2023
View article titled, Abstract CT228: Concordance between tissue and circulating tumor DNA (ctDNA) testing for neurotrophic tyrosine receptor kinase (<em>NTRK</em>) gene fusions in larotrectinib (laro) clinical trials
Journal Articles

Abstract 6127: MDM2 inhibition in combination with MEK inhibition in pre-clinical models of lung adenocarcinomas with MDM2 amplification

Arielle Elkrief, Vladimir Markov, Álvaro Quintanal-Villalonga, Rebecca Caeser, Pawel Sobczuk, Emily Cheng, Alexander Drilon, Gregory J. Riely, William W. Lockwood, Elisa de Stanchina, Charles M. Rudin, Igor Odintsov, Romel Somwar
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 6127.
https://doi.org/10.1158/1538-7445.AM2023-6127
Published: 04 April 2023
View article titled, Abstract 6127: MDM2 inhibition in combination with MEK inhibition in pre-clinical models of lung adenocarcinomas with <em>MDM2</em> amplification
Journal Articles

Abstract 6585: OncoKB, MSK’s precision oncology knowledge base

Sarah P. Suehnholz, Moriah Nissan, Hongxin Zhang, Ritika Kundra, Calvin Lu, Amanda Dhaneshwar, Nicole Fernandez, Stephanie Carrero, Maria E. Arcila, Marc Ladanyi, Michael F. Berger, Aijazuddin Syed, Rose Brannon, Ross Levine, Ahmet Dogan, Ezra Rosen, Alexander Drilon, David B. Solit, Nikolaus Schultz, Debyani Chakravarty
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 6585.
https://doi.org/10.1158/1538-7445.AM2023-6585
Published: 04 April 2023
View article titled, Abstract 6585: OncoKB, MSK’s precision oncology knowledge base
Journal Articles

Abstract 1144: Dynamic changes in circulating tumor DNA (ctDNA) in patients treated with sotorasib for KRAS G12C mutant non-small cell lung cancer

Yonina R. Murciano-Goroff, Ferdinandos Skoulidis, Vamsidhar Velcheti, Gerald S. Falchook, Grace Dy, Suresh Ramalingam, Martin J. Edelman, Jürgen Wolf, Antoine Italiano, Jorge S. Reis-Filho, Pedram Razavi, Alexander Drilon, Sandra Misale, Rona Yaeger, Mark Li, Antreas Hindoyan, Agnes Ang, Abraham A. Anderson, David Hong, Piro Lito, Ramaswamy Govindan, Bob T. Li
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 1144.
https://doi.org/10.1158/1538-7445.AM2023-1144
Published: 04 April 2023
View article titled, Abstract 1144: Dynamic changes in circulating tumor DNA (ctDNA) in patients treated with sotorasib for KRAS G12C mutant non-small cell lung cancer
Journal Articles

Abstract CT545: Variability in NTRK gene fusions does not appear to impact response to larotrectinib

Marc Ladanyi, Sinchita Roy-Chowdhuri, Lauren Ritterhouse, Felix Sahm, Ricarda Norenberg, Kui Shen, Chi Chen, Marc Fellous, Nicoletta Brega, Cornelis M. van Tilburg, Jessica J. Lin, Marcia S. Brose, Ulrik N. Lassen, Ray McDermott, Theodore W. Laetsch, David S. Hong, Alexander Drilon, Erin R. Rudzinski
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT545.
https://doi.org/10.1158/1538-7445.AM2022-CT545
Published: 15 June 2022
View article titled, Abstract CT545: Variability in <em>NTRK</em> gene fusions does not appear to impact response to larotrectinib
Journal Articles

Abstract 5239: Switching inhibitor class overcomes crizotinib resistance in a MET fusion-positive NSCLC with a novel acquired MET G1090A mutation

Yonina R. Murciano-Goroff, Srinivasaraghavan Kannan, Jason C. Chang, Ryma Benayed, Ilya Blokhin, Natasha Rekhtman, Ann Elizabeth Sisk, Jaime Gibson, Lia Judka, Lauren Kaplanis, Madeline Merrill, Erica Sgroe, Chandra S. Verma, Alexander Drilon, Emiliano Cocco
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 5239.
https://doi.org/10.1158/1538-7445.AM2022-5239
Published: 15 June 2022
View article titled, Abstract 5239: Switching inhibitor class overcomes crizotinib resistance in a MET fusion-positive NSCLC with a novel acquired MET G1090A mutation
Journal Articles

Abstract 5363: The preclinical selectivity and activity of APS03118, a highly selective and potent next-generation RET inhibitor

Alexander Drilon, Jun Zhong, Ying Lu, Yongbo Liu, Hao Wang, Minchun Chen, Xiaohu Chen, John Zhu, Shun Lu, Vivek Subbiah
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 5363.
https://doi.org/10.1158/1538-7445.AM2022-5363
Published: 15 June 2022
View article titled, Abstract 5363: The preclinical selectivity and activity of APS03118, a highly selective and potent next-generation RET inhibitor
Journal Articles

Abstract 868: Splicing factor mutant lung cancers: A comprehensive molecular and clinicopathologic characterization

Guilherme Harada, Christina J. Falcon, Fernando C. Santini, Jason C. Chang, Soo R. Yang, Maria E. Arcila, Natasha Rekhtman, Alexander Drilon
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 868.
https://doi.org/10.1158/1538-7445.AM2022-868
Published: 15 June 2022
View article titled, Abstract 868: Splicing factor mutant lung cancers: A comprehensive molecular and clinicopathologic characterization
Journal Articles

Abstract OT2-23-01: A Phase 1b/2a, open-label platform study to evaluate mirdametinib in combination with fulvestrant in ER+ metastatic breast cancers harboring MAPK-activating mutations

Ezra Y. Rosen, Payal Patel, Nenad Sarapa, Badreddin Edris, Alexia Iasonos, Komal Jhaveri, Pedram Razavi, Mark Robson, Alexander Drilon, Michael F. Berger, David B. Solit, Sarat Chandarlapaty
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): OT2-23-01.
https://doi.org/10.1158/1538-7445.SABCS21-OT2-23-01
Published: 15 February 2022
View article titled, Abstract OT2-23-01: A Phase 1b/2a, open-label platform study to evaluate mirdametinib in combination with fulvestrant in ER+ metastatic breast cancers harboring MAPK-activating mutations
Journal Articles

Abstract CT011: Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers

Vivek Subbiah, Bhavana Konda, Todd Bauer, Caroline McCoach, Gerald Falchook, Masayuki Takeda, Jyoti Patel, Jared Weiss, Nir Peled, Lyudmila Bazhenova, Victoria Soldatenkova, Pearl French, Nora Drove, Oliver Gautschi, Alexander Drilon
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT011.
https://doi.org/10.1158/1538-7445.AM2021-CT011
Published: 01 July 2021
View article titled, Abstract CT011: Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers
Journal Articles

Abstract CT020: Long-term outcomes of patients with TRK fusion cancer treated with larotrectinib

Alexander Drilon, Shivaani Kummar, Catherine M. Albert, Ramamoorthy Nagasubramanian, Jaclyn F. Hechtman, John A. Reeves, Georg Beckmann, Marion Rudolph, Justyna A. Wierzbińska, Laura Dima, Nicoletta Brega, Theodore W. Laetsch, David S. Hong
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT020.
https://doi.org/10.1158/1538-7445.AM2021-CT020
Published: 01 July 2021
View article titled, Abstract CT020: Long-term outcomes of patients with TRK fusion cancer treated with larotrectinib
Journal Articles

Abstract 1119: Molecular characteristics of repotrectinib that enable potent inhibition of TRK fusion proteins and broad mutant selectivity

Alexander Drilon, Dayong Zhai, Evan Rogers, Wei Deng, Xi Chen, Paul Sprengeler, Siegfried H. Reich, Brion W. Murray
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1119.
https://doi.org/10.1158/1538-7445.AM2021-1119
Published: 01 July 2021
View article titled, Abstract 1119: Molecular characteristics of repotrectinib that enable potent inhibition of TRK fusion proteins and broad mutant selectivity
Journal Articles

Abstract 1111: MYC promotes tyrosine kinase inhibitor resistance in ROS1 fusion positive lung cancers

Sudarshan R. Iyer, Igor Odintsov, Adam J. Schoenfeld, Hiroki Sato, Evan Siau, Alexander Drilon, Gregory J. Riely, Romel Somwar, Marc Ladanyi, Monika A. Davare
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1111.
https://doi.org/10.1158/1538-7445.AM2021-1111
Published: 01 July 2021
View article titled, Abstract 1111: MYC promotes tyrosine kinase inhibitor resistance in <em>ROS1</em> fusion positive lung cancers
Journal Articles

Abstract PS11-06: Efficacy and safety of larotrectinib in patients with TRK fusion breast cancer

Ezra Y. Rosen, Antoine Italiano, Dejan Juric, John A. Reeves, Laura Dima, Nicoletta Brega, Alexander Drilon
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS11-06.
https://doi.org/10.1158/1538-7445.SABCS20-PS11-06
Published: 15 February 2021
View article titled, Abstract PS11-06: Efficacy and safety of larotrectinib in patients with TRK fusion breast cancer
Journal Articles

Abstract CT199: Larotrectinib in TRK fusion cancer patients: Outcomes by prior therapy and performance status

Alexander Drilon, Cornelis M. van Tilburg, Anna F. Farago, Shivaani Kummar, Jordan Berlin, Catherine M. Albert, Ray McDermott, Ulrik N. Lassen, John A. Reeves, Nicoletta Brega, Barrett H. Childs, Theodore W. Laetsch, David S. Hong
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT199.
https://doi.org/10.1158/1538-7445.AM2020-CT199
Published: 15 August 2020
View article titled, Abstract CT199: Larotrectinib in TRK fusion cancer patients: Outcomes by prior therapy and performance status
Journal Articles

Abstract 5280: Kinase fusions drive endocrine resistance in estrogen receptor-positive breast cancer

Bo Liu, Dara S. Ross, Alison M. Schram, Pedram Razavi, Stephen M. Lagana, Yanming Zhang, Maurizio Scaltriti, Jacqueline F. Bromberg, Marc Ladanyi, David M. Hyman, Alexander Drilon, Ahmet Zahir, Ryma Benayed, Jaclyn F. Hechtman, Sarat Chandarlapaty
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 5280.
https://doi.org/10.1158/1538-7445.AM2020-5280
Published: 15 August 2020
View article titled, Abstract 5280: Kinase fusions drive endocrine resistance in estrogen receptor-positive breast cancer
Journal Articles

Abstract 5680: TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors

Emiliano Cocco, Ji Eun Lee, Srinivasaraghavan Kannan, Alison M. Schram, Helen H. Won, Sophie Shifman, Amanda Kulick, Laura Baldino, Eneda Toska, Sabrina Arena, Benedetta Mussolin, Ram Kannan, Neil Vasan, Alexander N. Gorelick, Michael F. Berger, Yi Liao, Uwe Rix, Alberto Bardelli, Jacklyn Hechtman, Elisa de Stanchina, David M. Hyman, Chandra Verma, Andrea Ventura, Alexander Drilon, Maurizio Scaltriti
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 5680.
https://doi.org/10.1158/1538-7445.AM2020-5680
Published: 15 August 2020
View article titled, Abstract 5680: TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors
Journal Articles

Abstract CT062: Efficacy and safety of larotrectinib in patients with cancer and NTRK gene fusions or other alterations

David S. Hong, Afshin Dowlati, Howard Burris, Edward Chu, Marcia S. Brose, Anna F. Farago, Cornelis M. van Tilburg, Shivaani Kummar, Leo Mascarenhas, John A. Reeves, Marion Rudolph, Patricia Maeda, Barrett H. Childs, Theodore W. Laetsch, Alexander Drilon
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT062.
https://doi.org/10.1158/1538-7445.AM2020-CT062
Published: 15 August 2020
View article titled, Abstract CT062: Efficacy and safety of larotrectinib in patients with cancer and <em>NTRK</em> gene fusions or other alterations
Journal Articles

Abstract CT192: Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2

Alexander Drilon, Fabrice Barlesi, Filippo De Braud, Byoung Chul Cho, Myung-Ju Ahn, Salvatore Siena, Matthew G. Krebs, Chia-Chi Lin, Tom John, Daniel SW Tan, Takashi Seto, Rafal Dziadziuszko, Hendrick-Tobias Arkenau, Christian Rolfo, Jürgen Wolf, Chenglin Ye, Todd Riehl, Susan Eng, Robert C. Doebele
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT192.
https://doi.org/10.1158/1538-7445.AM2019-CT192
Published: 01 July 2019
View article titled, Abstract CT192: Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2
Journal Articles

Abstract CT195: Long-term survival outcomes with nivolumab (NIVO) in pts with previously treated advanced non-small cell lung cancer (NSCLC): Impact of early disease control and response

Julie Brahmer, Hossein Borghaei, Suresh S. Ramalingam, Leora Horn, Esther Holgado, Adam Pluzanski, Marco A. Burgio, Marina Garassino, Laura Q. Chow, Scott Gettinger, Lucio Crino, David Planchard, Charles Butts, Alexander Drilon, Joanna Wojcik-Tomaszewska, Gregory Otterson, Vinny Hayreh, Ang Li, John R. Penrod, Scott J. Antonia
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT195.
https://doi.org/10.1158/1538-7445.AM2019-CT195
Published: 01 July 2019
View article titled, Abstract CT195: Long-term survival outcomes with nivolumab (NIVO) in pts with previously treated advanced non-small cell lung cancer (NSCLC): Impact of early disease control and response